Brief: Helix Biopharma Q2 loss per share C$0.03
16/03/2016 20:15
March 16 (Reuters) - Helix Biopharma Corp HBP.TO :
* Helix Biopharma Corp. announces second quarter fiscal 2016
results
* Cash reserves as at January 31, 2016 insufficient to see
current research and development initiatives through to
completion
* Management considers securing additional funds, expected
to be through issuance of equity securities of company
* Q2 loss per share C$0.03
* Cash reserves as at Jan 31, 2016, are insufficient to meet
anticipated cash needs for working capital and capital
expenditures through next 12 months
Source text for Eikon: urn:newsml:reuters.com:*:nCCN7r61PQ
Further company coverage: HBP.TO
((Bengaluru Newsroom; +1 646 223 8780;))
Recent news on Helix Biopharma
See all newsBrief: Helix Biopharma Reports Q3 Loss Per Share C$0.02
Brief: Helix Biopharma Intends To File Interim Consolidated Financial Statements By July 30
Brief: Helix Biopharma To Divest Remaining Ownership Of Polish Subsidiary
Brief: Helix Biopharma Says Expects To File Interim Disclosure Documents By July 30, 2020
Brief: Helix Biopharma Says L-Dos47 Phase I Lung Cancer Trial Data To Be Released At Asco 2020